Cell injection aims to repair damaged livers in early trial

NCT ID NCT07488546

ENROLLING_BY_INVITATION Disease control Sponsor: Shanghai Huicun Medical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a single injection of HCL001 cells in 39 people with decompensated cirrhosis, a severe form of liver disease. The study aims to check safety and see if the treatment can improve liver function. Participants receive one of three dose levels, and researchers will monitor them for up to 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HCL001 cell injection (a type of cell therapy)
What this could lead to: If successful, this could point toward a new treatment that improves liver function and reduces complications in people with advanced liver disease.
What could go wrong: This is a very early (Phase 1/2) trial with only 39 participants, so safety and effectiveness are not yet proven. Cell therapies can have unknown risks, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DECOMPENSATED CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DECOMPENSATED CIRRHOSIS

Contacts and locations

Locations

Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospita

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.